A noninvasive, AI-powered Doppler platform designed to catch peripheral artery disease years before symptoms appear.
Summary
ImageAiD is a medical technology company developing a portable, point-of-care Doppler ultrasound platform aimed at closing a longstanding gap in vascular diagnostics. Current screening relies heavily on ankle-brachial index (ABI) testing, which can produce false negatives in high-risk patients and becomes unreliable when arteries are calcified or noncompressible — limitations that mean vascular disease is often caught late, when treatment is more costly and outcomes are worse.
ImageAiD’s platform captures tibial arterial waveforms noninvasively, without arterial occlusion, and pairs that data with AI-supported analysis to help clinicians identify peripheral artery disease (PAD) earlier, potentially years before symptoms appear. The system is built as a three-step workflow — scan, analyze, act — producing structured output designed to fit directly into existing clinical workflows and reimbursement pathways. The company combines handheld hardware with a scalable software platform and has formed clinical collaborations with Mayo Clinic and Sutter Health.
ImageAiD is led by Founder and CEO Josh Hanson, an Arizona State University alum. The company is based in the Phoenix, Arizona area and was recently selected as part of a health care startup accelerator cohort alongside other diagnostics and biomedical engineering startups from across the U.S. and abroad.
Company Snapshot
- Industry: Medical Devices / Vascular Diagnostics
- Sector: Healthcare / Diagnostics / Medical Technology
- Focus: Peripheral Artery Disease Screening, Point-of-Care Vascular Diagnostics
- Technology: AI-Supported Doppler Ultrasound, Handheld Diagnostic Hardware
- Stage: Pre-Seed / Early-Stage
- Headquarters: Phoenix, AZ
- Website: https://www.imageaid.us/
Portfolio Manager Perspective
“ImageAiD stood out immediately — a diagnostic platform built for reimbursement and real-world adoption from day one.” Mike Shufeldt, MBA, Portfolio Manager
Company Overview
ImageAiD’s approach centers on a handheld Doppler device that captures arterial waveform data at the point of care in minutes, paired with software designed to support interpretation and deliver structured, workflow-aligned output. The goal is to make earlier identification of PAD practical in everyday clinical settings, without the occlusion, discomfort, or added procedural time associated with some existing methods.
The company has built early clinical relationships with Mayo Clinic and Sutter Health as it works to validate the platform, and has been recognized as part of a Phoenix-based health care innovation accelerator cohort focused on early detection technologies across vascular disease, cancer, and other conditions.
The Problem
Vascular disease affects a large and growing population, and existing screening tools leave clear room for improvement. ABI testing, the current standard, can miss high-risk patients and is distorted by noncompressible vessels — a common issue in diabetic and elderly populations. Late identification of vascular disease raises both clinical risk and treatment cost.
Why ImageAiD Stands Out
ImageAiD distinguishes itself through:
- Noninvasive, Point-of-Care Screening — captures tibial arterial waveforms in minutes, without arterial occlusion or added procedural time.
- AI-Supported Waveform Analysis — pairs handheld hardware with software that helps clinicians identify PAD earlier, potentially years before symptoms appear.
- Reimbursement-Compatible by Design — built as a scan, analyze, act workflow that produces structured output intended to fit existing clinical and reimbursement pathways.
- Early Clinical Validation — collaborations with Mayo Clinic and Sutter Health support the platform as it moves toward broader adoption.
- Accelerator Recognition — selected for a competitive Phoenix-based health care innovation accelerator cohort alongside other diagnostics and biomedical engineering startups.
Why We Invested
Vascular disease remains under-detected by today’s standard screening tools, and the cost of late diagnosis — in both patient outcomes and downstream treatment — is significant. Jetstream is drawn to companies that can shift diagnosis earlier using tools that fit naturally into existing clinical workflows rather than requiring wholesale changes to how care is delivered.
ImageAiD’s platform stood out for combining noninvasive, point-of-care hardware with AI-supported analysis in a way that is designed to be reimbursement-compatible from the outset — an important consideration for adoption in real clinical settings. Its early collaborations with health systems like Mayo Clinic and Sutter Health, along with its inclusion in a competitive health care innovation accelerator cohort, offer meaningful early validation of both the technology and the team behind it.
We see ImageAiD as an opportunity to back an early-stage company addressing a large, underserved diagnostic gap with a practical, scalable approach to earlier detection.
Leadership
- Josh Hanson – Founder & Chief Executive Officer
- Alex Richardson – Chief Technical Officer
